Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Cross Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• LKFT fell below its 200-day moving average, trading as low as $27.30 versus the $29.84 average, and last traded at $27.99.
• Analyst sentiment is predominantly cautious: seven analysts rate the stock “Hold” and one rates it “Strong Buy,” with an average price target of $30.67. Morgan Stanley and RBC both cut their targets to $26.
• The company exceeded quarterly expectations, reporting $0.04 earnings per share versus a consensus loss estimate of $0.97 and revenue of $15.47 million versus $7.29 million expected, though analysts still project a full-year loss.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $29.84 and traded as low as $27.30. Lakefront Biotherapeutics American Depositary Shares shares last traded at $27.99, with a volume of 329,243 shares traded.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on LKFT shares. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a "strong sell" rating to a "hold" rating in a research note on Monday, June 8th. Weiss Ratings lowered Lakefront Biotherapeutics American Depositary Shares from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, August 4th. Morgan Stanley cut their price target on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an "equal weight" rating for the company in a report on Tuesday, August 11th. Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a "buy" rating to a "hold" rating in a research report on Saturday, May 16th. Finally, Royal Bank Of Canada reduced their price objective on Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a "sector perform" rating for the company in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $30.67.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The business's 50 day moving average price is $28.67 and its 200-day moving average price is $29.84. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -19.85 and a beta of 0.27.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last issued its earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.97) by $1.01. The business had revenue of $15.47 million for the quarter, compared to analyst estimates of $7.29 million. On average, equities research analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Western Standard LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 4th quarter worth approximately $1,046,000. UBS Group AG boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 128.4% in the 4th quarter. UBS Group AG now owns 349,444 shares of the biotechnology company's stock valued at $11,427,000 after buying an additional 196,445 shares in the last quarter. Van ECK Associates Corp boosted its stake in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company's stock valued at $64,000 after buying an additional 750 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $211,000. Finally, Quadrant Capital Group LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the third quarter valued at $134,000. Institutional investors own 32.46% of the company's stock.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company's pipeline encompasses multiple programs across various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source